Title
Covaxin: An overview of its immunogenicity and safety trials in India
Authors
Rohit Sharma, Swati Tiwari & Aparna Dixit*
Affiliation
School of Biotechnology, Jawaharlal Nehru University, New Delhi - 110067, India; *Corresponding author
Aparna Dixit - E-mail: adixit7@gmail.com; adix2100@mail.jnu.ac.in; Rohit Sharma :rhox1522@gmail.com; Swati Tiwari: swati_tiwari@mail.jnu.ac.in
Article Type
Review Article
Date
Received August 17, 2021; Revised September 18, 2021; Accepted September 19, 2021, Published October 31, 2021
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global coronavirus disease-19 (COVID-19) pandemic. Several vaccine types, such as inactivated, viral vector-, or mRNA-based, have received approval against SARS-CoV-2. The ability to induceT-helper-1 cell (Th1) responses is desirable from an effective vaccine against this virus. Covaxin (BBV152) is a wholevirion inactivated SARS-CoV-2 vaccine adjuvanted with Algel-Imidazoquinoline (IMDG) molecule, a toll-like receptor (TLR) 7/8 agonist. The mRNA-based vaccine use is hindered because of cold storage requirement, whereas covaxin is stored between 2°C and 8°C, making it suitable for countries with limited resources. The Drug Controller General of India (DCGI) has approved the BBV152 vaccine. Therefore, it is of interest to document known data on BBV152 vaccine phase I, phase II and phase III human clinical trials to evaluate the safety, reactogenicity, tolerance, and immunogenicity of the whole-virion inactivated SARS-CoV-2 vaccine (BBV152).
Keywords
Covaxin, BBV152, COVID-19, animal and human trial, SARS-CoV-2 vaccine variants
Citation
Sharma et al. Bioinformation 17(10): 840-845 (2021)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
